Today: 19 May 2026
Browse Category

NASDAQ:IBRX 17 January 2026 - 18 May 2026

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio (IBRX) Stock Tumbles After FDA Warning on Anktiva Claims

ImmunityBio shares fell 21.1% Tuesday after the FDA posted a warning letter accusing the company of false or misleading claims about its cancer drug Anktiva in a TV ad and podcast. The FDA said the materials suggested Anktiva could cure or prevent all cancer, which is not approved. ImmunityBio has 15 working days to respond. Anktiva accounted for nearly all of the company’s $113 million in 2025 revenue.
25 March 2026
··
ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio stock jumps again in premarket as ANKTIVA sales surge puts IBRX in focus

ImmunityBio shares rose 3.5% to $11.95 premarket Wednesday after reporting 2025 net product revenue of $113 million for Anktiva, up about 700% year over year. The company posted a 2025 net loss of $351.4 million and ended the year with $242.8 million in cash. Investors await a March FDA meeting on recombinant BCG. Director Barry J. Simon sold 175,000 shares last week under a prearranged plan.
25 February 2026
·
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view

ImmunityBio shares rose about 1% to $8.70 premarket after reporting ANKTIVA net product revenue of $113 million for 2025, up roughly 700% from 2024. The company posted a $351.4 million net loss and ended the year with $242.8 million in cash. ANKTIVA is now authorized in 33 countries, including recent European approval. Traders are watching cash burn and upcoming regulatory milestones.
23 February 2026
·
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
··
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio shares climbed 5.9% to $6.26 Friday, rebounding from early losses despite declines in major biotech ETFs. The move followed a STAT News report that Chairman Patrick Soon-Shiong misrepresented an FDA meeting on Anktiva’s label expansion. Investors also tracked dilution risk after ImmunityBio amended a $505 million convertible note to allow partial conversions into stock.
30 January 2026
·
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next

ImmunityBio shares fell 1.6% to $6.35 after a filing showed looser conversion terms on a $505 million note held by an affiliate of executive chairman Patrick Soon-Shiong. The amendment allows partial conversions into stock, raising dilution concerns. About 16.8 million shares traded as the stock ranged from $6.28 to $6.92. New glioblastoma data will be presented Jan. 31.
26 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio shares fell 12.1% to $6.45 Friday after reporting median overall survival has not been reached in its Phase 2 glioblastoma trial. BTIG raised its price target to $9 and kept a Buy rating. The company said the FDA requested more data for its ANKTIVA bladder cancer application but no new trials. Preliminary 2025 net product revenue was reported at $113 million, up about 700% year-over-year.
24 January 2026
·
ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio stock price swings as new glioblastoma data hits; IBRX traders eye Jan. 31 update

ImmunityBio shares rose 2.7% to $7.54 Friday after updated Phase 2 data showed 19 of 23 glioblastoma patients still alive, with median overall survival unreached. Over 31 million shares traded as investors awaited more trial details at a Jan. 31 summit. The company reported 2025 ANKTIVA revenue of $113 million and year-end cash of $242.8 million. The stock has tripled in three weeks.
23 January 2026
·
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio shares fell 5.9% to $6.10 premarket after announcing an FDA meeting on possible resubmission of its ANKTIVA bladder-cancer drug. The FDA previously rejected the application for BCG-unresponsive papillary disease and has now requested more data. ImmunityBio plans to submit the information within 30 days. The company cites long-term trial data showing a 58.2% 12-month disease-free survival rate.
21 January 2026
·
Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio shares soared 40% to $5.52 Friday after the company reported preliminary 2025 net product revenue of $113 million and new approvals for ANKTIVA in Saudi Arabia. Trading volume topped 182 million shares. Enrollment in its key bladder cancer trial is over 85% complete, with FDA submission targeted by late 2026. Early data from its CAR-NK cell therapy showed complete remission in two Waldenström lymphoma patients.
18 January 2026
··
ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio stock (IBRX) ends week up 40% on ANKTIVA sales surge, fresh trial data — what’s next

ImmunityBio shares surged 39.8% to $5.52 Friday after the company projected 2025 ANKTIVA net product revenue of $113 million, up about 700% from last year. The stock rose further to $6.04 in after-hours trading. Trial enrollment for its bladder cancer study reached over 85%, and new CAR-NK data showed a 15-month complete response in Waldenström lymphoma.
18 January 2026
·
ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next

ImmunityBio shares jumped 39.9% to $5.52 Friday after reporting a sharp rise in preliminary 2025 ANKTIVA sales and positive trial updates. The company projected about $113 million in 2025 net product revenue for ANKTIVA, up nearly 700% from 2024. An interim analysis showed higher complete response rates for ANKTIVA plus BCG in bladder cancer. U.S. markets reopen Tuesday after the MLK Jr. holiday.
17 January 2026
·
1 2

Stock Market Today

  • iShares TIPS Bond ETF (TIP) Sees $141.1M Inflows, 0.8% Unit Growth
    May 19, 2026, 11:54 AM EDT. The iShares TIPS Bond ETF (TIP) experienced a significant weekly inflow of approximately $141.1 million, marking a 0.8% increase in units outstanding from 166.4 million to 167.7 million. TIP's latest share price stands near $108.72, within its 52-week range of $102.32 to $111.06. This ETF, which trades units like stocks, reflects buying demand that causes new unit creation, potentially influencing its underlying bond holdings. Monitoring such flows helps gauge investor sentiment and market impact. TIP's price relative to its 200-day moving average offers further technical context for traders assessing the ETF's momentum and strength.

Latest articles

Dow Jones Falls as Bond Yields Signal Trouble for Bulls

Dow Jones Falls as Bond Yields Signal Trouble for Bulls

19 May 2026
The Dow Jones Industrial Average dropped 249.36 points, or 0.5%, to 49,436.76 Tuesday morning as rising Treasury yields and oil prices pressured stocks. The 10-year Treasury yield hit 4.663%, its highest since January 2025. Brent crude stayed above $110 amid Middle East tensions. Home Depot reported first-quarter sales of $41.8 billion, up 4.8% from last year, and reaffirmed its 2026 outlook.
Whitecap Shares Touch 52-Week High as Buyers Stay In

Whitecap Shares Touch 52-Week High as Buyers Stay In

19 May 2026
Whitecap Resources shares hit a 52-week high of CA$17.04 in Toronto on Tuesday, up 1.6% intraday, after confirming a May dividend and raising 2026 production guidance. The company reported record Q1 output of 391,416 boe/d and kept its capital budget steady. The S&P/TSX Composite opened higher as U.S.-Iran tensions eased, while crude prices slipped but stayed elevated. Whitecap’s market value stood at about CA$20.59 billion.
Canaan Shares Drop on Mining Hardware Maker’s Wider Losses

Canaan Shares Drop on Mining Hardware Maker’s Wider Losses

19 May 2026
Canaan shares dropped 13.8% to $0.4163 after the company posted a Q1 net loss of $88.7 million and forecast lower Q2 revenue of $35 million to $45 million. Revenue fell to $62.7 million from $196.3 million in Q4. The company announced an 8 MW Nordic heat-reuse project. Trading volume exceeded 11.8 million shares.

Popular

Go toTop